Shares of Madrigal Pharmaceuticals (NASDAQ: MDGL) were soaring 15.2% higher as of 11:05 a.m. ET on Wednesday. The big gain ...

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) reported two-year results from the open-label compensated MASH cirrhosis (F4c) ...

Madrigal Pharmaceuticals, Inc.'s Rezdiffra, the first approved drug for MASH, showed strong sales growth, with Q4 net sales ...

Bill Sibold, Madrigal Pharmaceuticals CEO , joins 'Fast Money' to talk quarterly results.

Madrigal Pharmaceuticals (MDGL) reported Q4 results and provided a 2-year update from the open-label metabolic dysfunction-associated ...

JMP Securities analyst Jonathan Wolleben reiterated a Buy rating on Madrigal Pharmaceuticals (MDGL – Research Report) today and set a price ...

WEST CONSHOHOCKEN, Pa. (AP) — WEST CONSHOHOCKEN, Pa. (AP) — Madrigal Pharmaceuticals Inc. (MDGL) on Wednesday reported a loss of $59.4 million in its fourth quarter. The West Conshohocken, ...

Investing.com -- Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ: NASDAQ: MDGL) rose 17% following the announcement of their fourth-quarter and full-year 2024 financial results, which included a ...

The British drugmaker claimed study success in a first-line setting in breast cancer. Elsewhere, Rezdiffra sales continued to ...

Madrigal Pharmaceuticals (NASDAQ:MDGL – Get Free Report) will likely be posting its quarterly earnings results before the market opens on Wednesday, February 26th. Analysts expect Madrigal ...

Investors have grown concerned about the sector amid reports — which became reality — that President Trump would tap Robert F ...